^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IRAK-4 degrader

    Related drugs:
    13d
    Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)
    The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.
    Journal
    |
    TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)
    1m
    ADVANTA: Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=70, Terminated, Sanofi | Trial completion date: Aug 2026 --> Nov 2025 | Active, not recruiting --> Terminated; Sponsor decision. Not related to safety concern.
    Trial completion date • Trial termination
    1m
    ZEN: A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov)
    P2, N=70, Terminated, Sanofi | Trial completion date: Jul 2026 --> Nov 2025 | Active, not recruiting --> Terminated; Sponsor decision. Not related to safety concern.
    Trial completion date • Trial termination
    3ms
    ZEN: A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Sanofi | N=156 --> 70 | Trial primary completion date: Jun 2026 --> Oct 2025
    Enrollment change • Trial primary completion date
    3ms
    ADVANTA: Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Sanofi | N=200 --> 70 | Trial primary completion date: Jul 2026 --> Oct 2025
    Enrollment change • Trial primary completion date
    4ms
    Key cell cycle genes in cervical cancer and their potential role in neuromuscular complications: a bioinformatics perspective. (PubMed, Eur J Transl Myol)
    Gene expression profiles related to cervical cancer (GSE63514, GSE6791, GSE52903, and GSE9750) were retrieved from the GEO database...The specific genes associated with the cell cycle can act as prognostic biomarkers and may also have an influence in mediating neuromuscular complications due to their impact on mitotic control and molecular signaling pathways throughout the body. This latter aspect is helpful for the prognosis of cancer, including cervical cancer, as well as for the multidisciplinary treatment of neuromuscular symptoms that some cervical cancer patients may have.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • CCNA2 (Cyclin A2) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1)
    4ms
    A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov)
    P2, N=90, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old (clinicaltrials.gov)
    P1, N=78, Recruiting, Biogen | Not yet recruiting --> Recruiting
    Enrollment open
    5ms
    Downregulation of ANKRD22 and its prognostic significance in squamous cell carcinoma of the cervix: a bioinformatics analysis based on public datasets. (PubMed, Transl Cancer Res)
    Gene expression profiles were obtained from GEO datasets (GSE63514, GSE6791), and RNA sequencing and clinical data were obtained from The Cancer Genome Atlas...ANKRD22 downregulation is associated with poor prognosis in SCC of the cervix. While these findings suggest prognostic relevance, further experimental studies are necessary to validate ANKRD22's clinical utility.
    Journal
    |
    ANKRD22 (Ankyrin Repeat Domain 22)
    6ms
    A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, BeiGene
    New P2 trial
    7ms
    ADVANTA: Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    7ms
    ZEN: A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov)
    P2, N=156, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed